about
Palliative treatment of malignant ascites: profile of catumaxomab.Emerging treatment options for management of malignant ascites in patients with ovarian cancer.Intraperitoneally administered 90Y-labelled monoclonal antibodies as a third line of treatment in ovarian cancer. A phase 1-2 trial: problems encountered and possible solutions.Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer.Fibroblast recruitment as a tool for ovarian cancer detection and targeted therapyMatrix protein of vesicular stomatitis virus: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation.Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer.Endoscopic ultrasound-guided paracentesis of ascitic fluid: a morphologic study with ultrasonographic correlation.The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study.Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized study.
P2860
Q33892606-4E491EA2-361A-40C5-A2F8-13FAA07AD98CQ36173084-E3380E69-EE3C-479C-8C46-1A9B6797F546Q36290963-3E08FDD3-1F30-405E-933B-3146891A2666Q36358324-5A18F486-64DD-4EBE-B599-4A291296B0F1Q37225693-003F986C-1860-4656-B182-96FDEA71AE2AQ38767385-7340A2F2-044C-4017-A87C-0780F161F194Q39187132-DA54AE7A-2FE6-4145-8DCD-9BEEFA724DA5Q41552639-711E5F7F-A3A7-4B37-9F3C-FFCFE9A7F64CQ46288945-A3909E2F-D348-4681-A368-01B2F82EA702Q47301456-DE0637CE-448C-4D3F-84BD-FC3C098A6595Q47375149-937F4E00-0418-41ED-8AD5-BE53A343CE95Q51140743-D119A2CB-FEE2-4C99-ACE1-F86F3530F062
P2860
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh-hant
name
Mechanisms of malignant ascites production.
@en
Mechanisms of malignant ascites production.
@nl
type
label
Mechanisms of malignant ascites production.
@en
Mechanisms of malignant ascites production.
@nl
prefLabel
Mechanisms of malignant ascites production.
@en
Mechanisms of malignant ascites production.
@nl
P2093
P1476
Mechanisms of malignant ascites production.
@en
P2093
Galloway RH
Garrison RN
P304
P356
10.1016/0022-4804(87)90109-0
P577
1987-02-01T00:00:00Z